FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to drugs and concerns the application of CB1 receptor antagonist representing N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or one of its pharmaceutically acceptable salts in preparing a composition for treating hepatic fibroses. Also the method of treating hepatic fibroses in mammals is disclosed.
EFFECT: invention aims at preparation of a drug for treating hepatic fibrosis.
13 cl, 4 dwg, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| CB1 RECEPTOR ANTAGONISTS | 2012 |
|
RU2593751C2 |
| TREATMENT OF HEPATIC ADIPOSITIS WITH APPLICATION OF GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | 2015 |
|
RU2718921C2 |
| PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | 2012 |
|
RU2678561C9 |
| PEPTIDES INHIBITING GROWTH TRANSFORMING FACTOR TGF-BETA-1 | 1999 |
|
RU2232771C2 |
| HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
| METHOD OF PREVENTION AND TREATMENT OF LIVER DISEASE WITH APPLICATION OF RECEPTOR A ANTAGONISTS | 2007 |
|
RU2457842C2 |
| USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
| VAP-1 INHIBITORS ADMINISTRATION FOR FIBROID DISEASES TREATMENT | 2010 |
|
RU2667963C1 |
| ANTAGONISTS OF ALPHAVBETA3 AND ALPHAVBETA6 INTEGRINS AND ANTIFIBROTIC AGENTS | 2004 |
|
RU2388472C2 |
